Abstract: A process for preparing polyether-modified amino-functional polybutadienes involves a) reacting at least one polybutadiene (A) with at least one epoxidizing reagent (B) to give at least one epoxy-functional polybutadiene (C); b) reacting the at least one epoxy-functional polybutadiene (C) with at least one amino-functional compound (D) to give at least one hydroxy- and amino-functional polybutadiene (E); and c) reacting the at least one hydroxy- and amino-functional polybutadiene (E) with at least one epoxy-functional compound (F) to give at least one polyether-modified amino-functional polybutadiene (G). The polyether-modified amino-functional polybutadienes preparable by this process are also provided.

Abstract: The present invention relates to compounds that modulate the conformation of Aurora Kinase A (AURKA). The compounds of the present invention are also modulators of the interactome of AURKA, and preferably alter the protein-protein interaction of AURKA with binding proteins, such as MYC and/or TPX2. The present invention also pertains to the use of such compounds in the prevention and/or treatment of proliferative diseases, such as cancer, and kits comprising the same.

Abstract: A tissue-targeting complex is described that comprises at least one targeting element [A-L-Q+-Alk B-] in which A is an amino-containing anchor element, L a linker, Q+ a quaternary ammonium group, B- an ophthalmologically acceptable counterion, and Alk an alkyl chain having 4 to 12 carbon atoms; at least one chromophore, and optionally a carrier molecule.

Abstract: A syringe device and a syringe system with a syringe device provides an ergonomic syringe device which enables safe operation and safe injection by using a pen-like syringe device having a drive housing, a syringe receptacle for receiving a syringe having a syringe body and a plunger guided therein, and a manually operable push button for activating an electrical delivery unit. The drive housing has a pressure supply unit for pneumatically actuating the plunger and a coupling connection for connection to an external supply unit. The pressure supply unit includes a drive channel which can be connected to the plunger of an inserted syringe. The syringe device has a vent channel connected to the drive channel and via an opening to the environment, the opening being closable by a finger when the push button is actuated.

Abstract: The invention relates to a flywheel for stabilising the position of a spacecraft, comprising a hub means (1) for fastening the flywheel, a flywheel ring (4), which externally surrounds the hub means (1) circumferentially at a distance, a support means (3) for supporting the flywheel ring (4) on the hub means (1), and a vibration damping device (6, 8) having a tuned mass damper means (8) which is axially movable back and forth relative to the flywheel ring with respect to a rotation axis of the flywheel.

Abstract: A pen-like syringe system includes: a syringe holder for receiving a syringe having a syringe barrel and a plunger guided for movement in the barrel; and a drive housing connected to the syringe holder. To provide an ergonomic syringe system which allows advantageous operation of the system and guarantees safe and focused injection or drawing of a substance the drive housing includes an electric delivery device operated by an integrated power supply for applying pneumatic pressure or negative pressure to the plunger, with the delivery device connected via a drive channel to the plunger and actuatable by a button arranged on the syringe system; and the pen-like syringe system has a vent duct with a first end, which is connected to the drive channel, and a second end, which is connected to the surroundings via an opening, with the opening closable by pressing the button.

Abstract: The invention relates to a flywheel for stabilising the position of a spacecraft, comprising a hub means (1) for fastening the flywheel, a flywheel ring (4), which externally surrounds the hub means (1) circumferentially at a distance, a support means (3) for supporting the flywheel ring (4) on the hub means (1), and a vibration damping device (6, 8) having a tuned mass damper means (8) which is axially movable back and forth relative to the flywheel ring with respect to a rotation axis of the flywheel.

Abstract: The invention relates to modified polysaccharide ethers having a weight-averaged molecular weight of 40,000 to 500,000 g/mole, zero shear viscosity of more than 10 Pa·s, and pseudo-plasticity of more than 20. These modified polysaccharide ethers are obtainable by reacting cellulose-based polysaccharide ether(s) with at least one mesogenic modification agent or modified polysaccharide ethers, obtainable by reacting polysaccharide ether(s) selected from hydroxypropylmethyl cellulose (HPMC), hydroxyethylmethyl cellulose (HEMC), methyl cellulose, and cellulose ethers with methyl and/or ethyl and/or propyl groups and mixtures thereof, with at least one mesogenic modification agent. These substances can be used to produce gel-like to stable aqueous preparations having viscoelastic flow properties, which are suited for use in the human body, particularly within the scope of ophthalmologic procedures.

Abstract: An activated carbon catalyst is described which is sufficiently active in the presence of catalytic poisons in crude gas to convert nitrogen oxides to nitrogen in the presence of ammonia.

Abstract: Process for producing activated carbon having a high catalytic activity, in which a carbonaceous material is brought into contact with nitrogen compounds, wherein the carbonaceous material is partially gasified with a mixture of steam, nitrogen and CO2 at temperatures above 800° C. in a manner known per se in a multistage fluidized bed and wherein a nitrogen compound is added into the furnace and/or at least one stage of the multistage fluidized bed.

Abstract: The invention relates to modified polysaccharide ethers having a weight-averaged molecular weight of 40000 to 50000 g/mole, zero shear viscosity of more than 10 Pas, and pseudoplasticity of more than 20, obtainable by reacting cellulose-based polysaccharide ether(s) with at least one mesogenic modification agent or modified polysaccharide ethers, obtainable by reacting polysaccharide ether(s) selected from the group consisting of hydroxypropylmethyl cellulose (HPMC), hydroxyethylmethyl cellulose (HEMC), methyl cellulose, and cellulose ethers with methyl and/or ethyl and/or propyl groups and mixtures thereof, with at least one mesogenic modification agent. Said substances can be used to produce gel-like to stable aqueous preparations having viscoelastic flow properties, which are suited for use in the human body, particularly within the scope of ophthalmologic procedures.

Abstract: A process is disclosed for preparing (3R,4R)-3-hydroxy-4-hydroxymethylpyrrolidine, the compound of formula (I), or (3S,4S)-3-hydroxy-4-hydroxymethylpyrrolidine, the compound of formula (Ia) involving, as a key step, the enzyme-catalysed enantioselective hydrolysis of a racemic 3,4-trans-disubstituted pyrrolidinone compound of formula (II).

Abstract: The present invention relates to compounds of the general formula (I) which are inhibitors of purine muclioside phosphorylases (PNP), purine phosphoribosyltransferases (PPRT), 5?-methylthioadenosine phosphorylases (MTAP), 5?-methylthioadenosine mucliosidases (MTAN) and/or nucleoside hydrolases (NH). The invention also relates to the use of these compounds in the treatment of diseases and infections including cancer, bacterial infections, protozoal infections, and T-cell mediated disease and to pharmaceutical compositions containing the compounds.

Abstract: Process for producing activated carbon having a high catalytic activity, in which a carbonaceous material is brought into contact with nitrogen compounds, wherein the carbonaceous material is partially gasified with a mixture of steam, nitrogen and CO2 at temperatures above 800° C. in a manner known per se in a multistage fluidised bed and wherein a nitrogen compound is added into the furnace and/or at least one stage of the multistage fluidised bed.

Abstract: An activated carbon catalyst is described which is sufficiently active in the presence of catalytic poisons in crude gas to convert nitrogen oxides to nitrogen in the presence of ammonia.

Abstract: The present invention relates to compounds of the general formula (I) which are inhibitors of purine nucleoside phosphorylases (PNP), purine phosphoribosyltransferases (PPRT), 5?-methylthioadenosine phosphorylases (MTAP), 5?-methylthioadenosine nucleosidases (MTAN) and/or nucleoside hydrolases (NH). The invention also relates to the use of these compounds in the treatment of diseases and infections including cancer, bacterial infections, protozoal infections, and T-cell mediated disease and to pharmaceutical compositions containing the compounds.

Abstract: The present invention relates to compounds of the general formula (I) which are inhibitors of purine muclioside phosphorylases (PNP), purine phosphoribosyltransferases (PPRT), 5?-methylthioadenosine phosphorylases (MTAP), 5?-methylthioadenosine mucliosidases (MTAN) and/or nucleoside hydrolases (NH). The invention also relates to the use of these compounds in the treatment of diseases and infections including cancer, bacterial infections, protozoal infections, and T-cell mediated disease and to pharmaceutical compositions containing the compounds.

Abstract: A process is disclosed for preparing (3R,4R)-3-hydroxy-4-hydroxymethylpyrrolidine, the compound of formula (I), or (3S,4S)-3-hydroxy-4-hydroxymethylpyrrolidine, the compound of formula (Ia) involving, as a key step, the enzyme-catalysed enantioselective hydrolysis of a racemic 3,4-trans-disubstituted pyrrolidinone compound of formula (II).

Abstract: The invention includes a method for the passivation of the surface of an intraocular lens, wherein the surface includes Brönsted sites. The intraocular lens is dipped into a solution of a fluoroalkyl silane having the general formula: Rf—(CH2)n—Si—(O—R)3. The residue R is selected from the group of H, CH3, C2H5 and C3H7 and the fluoroalkyl residue Rf is selected from the series CF3(CF2)m, with m=3 to 11 and n=0 to 4. The Brönsted sites on the surface are thereby deactivated by formation of Si—Q—bonds.

Abstract: The invention relates to a plastically deformable implant for inserting into bodily orifices of the human or animal body. Implants of this type are used, for example, in ophthalmology, in particular, as vitreous body or lens replacements and in dentistry, for example, for filling extraction cavities in jaw-bones. Known implants, however, are not suitable for long-term use. The invention aims to provide a deformable plastic implant which also has a long-term application. This is achieved by the fact that the implant consists of a gel which is not sealed, containing fluorocarbon and which is directly introduced into the natural, or artificially created bodily orifice.